Puma Biotechnology (PBYI) 30.62 $PBYI PBYI August 5th

New Post Public Reply Private Reply Replies (0) Message Board

Jun 25, 2016 at 4:20 AM

Puma Biotechnology (PBYI) 30.62 $PBYI

PBYI August 5th Options Begin Trading
DividendChannel.com - Thu Jun 23, 9:43AM CDT
Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 5th expiration.
PBYI: 30.62 (-3.03)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.06 (-0.65), JAZZ: 137.90 (-7.10), GRFS: 15.50 (-0.58), PBYI: 30.62 (-3.03)

Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 54.34 (-1.93), AZN: 27.86 (-1.43), RTRX: 17.80 (-0.69), PBYI: 30.62 (-3.03)

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 30.62 (-3.03)

Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.52 (-0.03), PBYI: 30.62 (-3.03)

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 30.62 (-3.03)

Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 54.34 (-1.93), RTRX: 17.80 (-0.69), BMY: 70.61 (-2.03), PBYI: 30.62 (-3.03)

Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 30.62 (-3.03)

Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 30.62 (-3.03)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.27 (-0.12), INO: 9.17 (-0.68), VVUS: 1.10 (unch), TEVA: 50.01 (-1.36), ARNA: 1.81 (-0.10), PBYI: 30.62 (-3.03)

What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 29.26 (-1.07), JAZZ: 137.90 (-7.10), PBYI: 30.62 (-3.03)

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 30.62 (-3.03)

Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 30.62 (-3.03)

Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 8:21AM CDT
Image source: Puma Biotechnology. What: Shares of Puma Biotechnology , a biopharmaceutical company dedicated to development of novel cancer therapies, fell 36.6% last month, according to data from S&P Global Market Intelligence . ...
PBYI: 30.62 (-3.03)

Why is Puma Biotech Stock (PBYI) Plummeting Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:04PM CDT
Puma Biotechnology is having a terrible day of trading. Why is that?
PBYI: 30.62 (-3.03)

Puma's (PBYI) Filing for Breast Cancer Drug Neratinib Delayed
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 10:20AM CDT
Puma Biotechnology (PBYI) announced that the regulatory filing for its breast cancer drug neratinib will be delayed until mid-2016.
AMAG: 23.42 (-1.47), ANIK: 51.09 (-0.01), PBYI: 30.62 (-3.03)

Puma Biotechnology Updates Timeline for Filing New Drug Application
BusinessWire - Mon Mar 28, 3:10PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.S. Food and Drug Administration (FDA), the Company now plans to submit its New Drug Application (NDA) for the approval of neratinib for the treatment of extended adjuvant breast cancer that has previously been treated with a trastuzumab-containing regimen in mid-2016.
PBYI: 30.62 (-3.03)

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
BusinessWire - Fri Mar 18, 7:30AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2016. The AACR Annual Meeting will be held at the Ernest N. Morial Convention Center in New Orleans from April 16 to April 20.
PBYI: 30.62 (-3.03)

Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 76.98 (-4.68), IMGN: 3.13 (-0.19), ARQL: 1.91 (-0.01), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), ONTY: 1.21 (+0.02), MDVN: 56.95 (-2.31), MRK: 55.88 (-1.80), AZN: 27.86 (-1.43), AVEO: 0.95 (-0.03), GALE: 2.10 (-0.05), PBYI: 30.62 (-3.03), NVS: 77.10 (-3.57), KPTI: 7.52 (-0.51), XLRN: 33.46 (-1.58), EXEL: 7.69 (-0.16)

Puma Biotechnology to Present at Cowen's Health Care Conference
BusinessWire - Wed Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m. EST on Wednesday, March 9, at the Cowen and Company 36th Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place.
PBYI: 30.62 (-3.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cousins Lobster Hits Arkansas for Tasty Pop-Up Tour

A New England Delicacy Rolling into Arkansas Folks in Northwest Arkansas are about to get a bite of the coast, and it's a big deal for any foodie out there who craves that authentic, no-frills lobster experience. Cousins Maine Lobster is setting out on a pop-up tour—a whirlwind of five days from November 11-15—bringing their joy-inducing lobster rolls straight from...

Zoomlion's 1,600HP 9DX Tractor Aims at Global Farms

Zoomlion's Bold Move into the Global Market Zoomlion Heavy Industry is skipping right into the big leagues with their newest toy—sorry, tractor—the 9DX hybrid, packed with a staggering 1,600 horsepower. Making a splash at the China International Agricultural Machinery Exhibition, this beast is fired up for large-scale farming, and it's aiming to reshape the...

Embraer ADS Ratio Change: Impact on Investors

ADS Ratio Adjustments: What's the Big Deal? Well, here we go. Embraer, that Brazilian aerospace heavyweight, has just kicked up some dust with its latest move concerning American Depositary Shares (ADS). Now, don't expect any shock and awe value-explosion gimmicks, but there's a shift in the air. Understanding the Split Let's cut to the financial meat: Embraer’s mucking...

PenFed Credit Union's Soaring Loan Originations in Q3 2026

Staggering Growth in Loan Originations Ever wake up to an unexpected windfall? That's the kind of headline PenFed Credit Union is writing with its $8.8 billion in year-to-date loan originations by the end of September 2026. Up 22% year-over-year, folks. Those numbers don't just happen by accident. That's hitting the nail on the head in the credit union world. Mortgage and...

Stora Enso Plans Bold Demerger; Bergslagets Skogar to List

Stora Enso's Strategic Split: Bold Move or Risky Bet? There's something almost audacious about Stora Enso's decision to separate Bergslagets Skogar into its own publicly listed company. The board has given this demerger plan the green light, aiming to unravel a more refined operation out of Stora Enso's labyrinthine portfolio. It's a move that should have the suits on...

Haunted Attraction Insights from the Queen of Haunts

Admit it—everyone's got that one fear that sends shivers down their spine. Whether it's the slithering scales of a snake or the manic laughter of a clown, those phobias are what make haunted attractions such a hit for thrillseekers across the country. Amber Arnett-Bequeaith, the so-called Queen of Haunts, knows a thing or two about turning those fears into unforgettable...

Z Squared Eyes 150 MW Expansion at Arkansas Site

Turning Power into Potential at Union County Next stop, Union County, Arkansas. Z Squared Inc. (Nasdaq: ZSQR) isn't just talking shop; they're getting down to work. With a freshly acquired site through Paradox Data, LLC, Z Squared's planning to turn vision into reality. The site's already armed with 8 MW of juice, all ready to roll, but their ambitions shoot up to 150 MW...

Hot Chili Sizzles with La Verde Copper Drill Gains

Big Copper Moves at La Verde: What's New? Look, when it comes to copper, Hot Chili Limited is throwing down some serious markers. You see, their La Verde project is turning into a hotbed of activity thanks to their latest drilling revelations. They've managed to confirm a second porphyry center, which is like finding another gold mine, except with copper. This essentially...

Nanoscope Therapeutics Aims for Eye-Catching Advances

Gearing Up for a Boston Showcase Nanoscope's High-Stakes Boston Rendezvous In a move set to grab some serious eyeballs, Nanoscope Therapeutics is geared up to strut their stuff at Advanced Therapies USA 2026 in Boston. Scheduled for November 4–5 at the Hynes Convention Center, the event isn't just another pitstop—it's a billboard for what these guys have cooking. With...

Trade Cases on Pizza Box Imports Set Industry Ablaze

U.S. Takes Stand Against Unfair Import Practices Who knew pizza boxes could stir up such a fuss, huh? Well, here we are. The U.S. International Trade Commission (ITC) has sided with American pizza box manufacturers, waving the flag against those sneaky imports from China, Malaysia, and Turkey. According to the ITC, these imports are causing some real headaches for the...